跳转至内容
Merck
CN

V900185

乙酰水杨酸

Vetec, reagent grade, ≥99%

别名:

2-乙酰氧基苯甲酸, O-乙酰水杨酸, ASA, 阿司匹林

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
2-(CH3CO2)C6H4CO2H
化学文摘社编号:
分子量:
180.16
EC Number:
200-064-1
UNSPSC Code:
41116107
PubChem Substance ID:
Beilstein/REAXYS Number:
779271
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

SMILES string

CC(=O)Oc1ccccc1C(O)=O

grade

reagent grade

product line

Vetec

assay

≥99%

form

powder

Gene Information

solubility

ethanol: 50 mg/mL, clear, colorless

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

通过抑制环氧化酶(前列腺素H合酶),对COX-1亚型具有更高的选择性,阻止前列腺素的产生。抗血栓作用是由于COX-1在血小板中的抑制作用,阻止血栓形成和血小板聚集。 对结直肠及其他实体肿瘤有化学预防作用。

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

482.0 °F - closed cup

flash_point_c

250 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Fabrizio D'Ascenzo et al.
The American journal of cardiology, 115(9), 1185-1193 (2015-03-24)
The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulants (OACs) is currently debated. MEDLINE and Cochrane Library were searched for studies reporting outcomes of patients who underwent PCI and who were on triple therapy (TT) or dual-antiplatelet
Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
Reiko Nishihara et al.
JAMA, 309(24), 2563-2571 (2013-06-27)
Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin
P J Devereaux et al.
The New England journal of medicine, 370(16), 1494-1503 (2014-04-01)
There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are not. Using a 2-by-2 factorial trial design, we randomly assigned

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持